The tuberculosis vaccine market is primarily driven by the high prevalence of tuberculosis globally and the increasing demand for effective vaccines. The development of new vaccines with enhanced efficacy and better safety profiles is also contributing to the growth of the market. However, the lack of awareness and poor healthcare infrastructure in some regions are restraining factors. In addition, the lengthy regulatory approval process and the high cost associated with vaccine development and production are also challenges faced by market players. The key players in the market are focusing on collaborations and partnerships to expand their product portfolio and increase their market share. The COVID-19 pandemic has also affected the market, with disruptions in the supply chain and delays in clinical trials and regulatory approvals. Overall, the Tuberculosis Vaccine Market is expected to grow in the coming years, driven by increasing investments in research and development and the rising demand for effective tuberculosis vaccines.
Leading Companies in the Tuberculosis Vaccine Industry:
1. GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company founded in 2000. It is headquartered in Brentford, United Kingdom, and operates in over 100 countries worldwide. In October 2020, GSK announced positive results from a phase 2b trial of its tuberculosis vaccine candidate, M72/AS01E, which showed a 50% reduction in the incidence of pulmonary tuberculosis compared to placebo.
2. Sanofi Pasteur
Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. It was founded in 1999 and is headquartered in Lyon, France. Sanofi Pasteur operates in over 170 countries worldwide. In December 2021, the company announced the initiation of a phase 3 trial of its tuberculosis vaccine candidate, M72/AS01E2, in HIV-positive adults in sub-Saharan Africa.
3. Longcom Enterprise Ltd
Longcom Enterprise Ltd is a Chinese pharmaceutical company founded in 1993. It is headquartered in Shanghai, China, and operates in several countries worldwide. In November 2021, Longcom Enterprise Ltd announced the completion of a phase 2 trial of its tuberculosis vaccine candidate, LC53, which showed promising safety and immunogenicity results.
4. Biofabri
Biofabri is a Spanish biopharmaceutical company founded in 2008. It is headquartered in León, Spain, and operates in several countries worldwide. In October 2021, Biofabri announced the initiation of a phase 2b trial of its tuberculosis vaccine candidate, BCG+MVA85A, in adolescents in South Africa.
5. Valneva plc
Valneva plc is a French biotech company founded in 2013. It is headquartered in Saint-Herblain, France, and operates in several countries worldwide. In October 2021, Valneva plc announced the initiation of a phase 2 trial of its tuberculosis vaccine candidate, VLA84, in adults in the United States.
6. Archivel Farma S.L.
Archivel Farma S.L. is a Spanish biotech company founded in 2011. It is headquartered in Barcelona, Spain, and operates in several countries worldwide. In October 2021, Archivel Farma S.L. announced the initiation of a phase 2 trial of its tuberculosis vaccine candidate, M11, in adults in Spain.
Definition- A tuberculosis (TB) vaccine is a medication that provides protection against tuberculosis, a serious and potentially deadly infectious disease caused by the bacterium Mycobacterium tuberculosis
